Latest news with #Afib
Business Wire
2 days ago
- Business
- Business Wire
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results. Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio, particularly in our AtriClip platform and cryoSPHERE device offerings. Share 'Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio, particularly in our AtriClip platform and cryoSPHERE device offerings. We're seeing increasing momentum as our new technologies drive deeper adoption, reduced procedure times, and improved patient outcomes,' said Michael Carrel, President and Chief Executive Officer at AtriCure. 'With this foundation, we're excited about the opportunities ahead in the second half of 2025 and beyond to continue delivering strong growth and expanding profitability.' Second Quarter 2025 Financial Results Revenue for the second quarter 2025 was $136.1 million, an increase of 17.1% over second quarter 2024 revenue (16.5% on a constant currency basis), reflecting continued adoption of our products and therapies globally for the treatment of Afib, LAA management and post-operative pain management. U.S. revenue was $110.6 million, an increase of $15.0 million or 15.7%, compared to the second quarter 2024. U.S. revenue growth was driven by sales across key product lines, including the AtriClip ® FLEX·Mini ™ device for appendage management, the EnCompass ® clamp for open ablation and the cryoSPHERE MAX ™ probe for post-operative pain management. International revenue increased $4.8 million or 23.3% (19.9% on a constant currency basis) to $25.6 million, realizing significant growth across all franchises and geographic regions. Gross profit for the second quarter 2025 was $101.5 million compared to $86.8 million for the second quarter 2024. Gross margin was 74.5% for the second quarter 2025, a decrease of 15 basis points from the second quarter 2024, reflecting less favorable geographic and product mix. Loss from operations for the second quarter 2025 was $6.2 million, compared to $7.2 million for the second quarter 2024. Basic and diluted net loss per share was $0.13 for the second quarter 2025, compared to $0.17 for the second quarter 2024. Adjusted EBITDA for the second quarter 2025 was $15.4 million, an increase of $7.6 million from second quarter of 2024. Adjusted loss per share for the second quarter 2025 was $0.02, compared to $0.17 for the second quarter 2024. Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP financial measures. We discuss these non-GAAP financial measures and provide reconciliations to GAAP measures later in this release. 2025 Financial Guidance Full year 2025 revenue is now projected to be approximately $527 million to $533 million, and management now expects full year 2025 Adjusted EBITDA of approximately $49 million to $52 million. Full year 2025 adjusted loss per share is expected to be in the range of $0.34 to $0.39. Additionally, management expects modest cash flow generation for the full year 2025. Conference Call AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 29, 2025 to discuss second quarter 2025 financial results. To access the webcast, please visit the Investors page of AtriCure's corporate website at Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure's Isolator ® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE ® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X @AtriCure. Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data; competition from existing and new products and procedures, including the development of drugs or catheter-based technologies; our reliance on independent distributors to sell our products; inventory-related charges; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; impacts of rising healthcare costs; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; unfavorable publicity; the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make; disruptions to our manufacturing operations; the impact of tariffs or other restrictive trade measures; our failure to properly manage growth; disruptions of critical information systems or material breaches in the security of our systems; our ability to manage our intellectual property rights to provide meaningful protection; fluctuation of quarterly financial results; fluctuations in foreign currency exchange rates; reliance on third party manufacturers and suppliers; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 14, 2025, and our quarterly reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Use of Non-GAAP Financial Measures To supplement AtriCure's condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics. Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors. Adjusted EBITDA is calculated as net loss before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, and non-recurring charges that are not reflective of the operational results of the Company's core business and may affect comparability of results period-over-period. Non-recurring charges include acquisition costs, acquired-in-process research and development (IPR&D) and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned 'Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)' later in this release. Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, acquired IPR&D and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and debt extinguishment. A reconciliation of adjusted loss per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned 'Reconciliation of Non-GAAP Adjusted Loss Per Share' later in this release. The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure's financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business. ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) (Unaudited) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 117,796 $ 122,721 Accounts receivable, net 66,004 60,339 Inventories 76,344 75,335 Prepaid and other current assets 11,113 9,431 Total current assets 271,257 267,826 Property and equipment, net 40,681 41,659 Operating lease right-of-use assets 7,086 5,727 Goodwill and intangible assets, net 287,027 291,248 Other noncurrent assets 2,798 2,868 Total Assets $ 608,849 $ 609,328 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued liabilities $ 65,935 $ 70,619 Current lease liabilities 2,908 2,805 Total current liabilities 68,843 73,424 Long-term debt 61,865 61,865 Finance and operating lease liabilities 12,478 11,860 Other noncurrent liabilities 1,172 1,210 Total Liabilities 144,358 148,359 Stockholders' Equity: Common stock 50 49 Additional paid-in capital 878,384 863,710 Accumulated other comprehensive income (loss) 749 (1,035 ) Accumulated deficit (414,692 ) (401,755 ) Total Stockholders' Equity 464,491 460,969 Total Liabilities and Stockholders' Equity $ 608,849 $ 609,328 Expand ATRICURE, INC. AND SUBSIDIARIES (In Thousands) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss, as reported $ (6,190 ) $ (8,008 ) $ (12,937 ) $ (21,277 ) Income tax expense 261 253 500 436 Other income (expense), net (263 ) 587 291 2,756 Depreciation and amortization expense 5,171 4,527 10,255 8,979 Share-based compensation expense 11,371 10,391 21,001 19,656 Acquired in-process research & development expense 5,000 — 5,000 — Expand
Yahoo
4 days ago
- Business
- Yahoo
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
MASON, Ohio, July 28, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference. AtriCure's management is scheduled to present on Tuesday, August 12, 2025, at 2:30 p.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X @AtriCure. View source version on Contacts Angie WirickAtriCure, Financial Officer(513) 755-5334awirick@ Marissa BychGilmartin GroupInvestor Relationsmarissa@
Dominion Post
6 days ago
- Health
- Dominion Post
Mon Medical Center participates in trial for device that could revolutionize Afib treatment
dbeard@ MORGANTOWN – Vandalia Health Mon Medical Center is participating in a clinical trial that could forever change how patients with atrial fibrillation are treated. The trial is called Catalyst, for the Abbott Medical Devices Amplatzer Amulet Left Atrial Appendage Occluder. The Amulet is already in use for Afib patients who can't use oral anticoagulants (blood thinners), said Dr. Wissam Gharib, who is leading the trial at Mon Medical. But this could broaden its use to all Afib patients, he said. This trial, he said, follows a similar trial, called Champion-AF, for the Watchman device by Boston Scientific. If the trials are successful, he said, 'This will be a paradigm shift in how we treat patients.' Abbott describes Afib as irregular electrical impulses in the upper chambers of the heart that cause those chambers to fibrillate, or quiver. This results in an irregular and frequently rapid heart rate that affects the heart's ability to pump blood, allowing blood to pool and collect in the left atrial appendage. Abbott explains that there is a muscular pouch connected to the left atrium of the heart called the left atrial appendage. If the blood clots are pumped from the appendage out into the body, the clots may flow to the brain and lead to stroke. The Amulet and the Watchman are both inserted via catheter to seal off the left atrial appendage. Gharib explains that patients diagnosed with Afib are first treated with blood thinners. For those who can't tolerate the medications, the Amulet and the Watchman provide an alternative approved by the FDA. The Catalyst and Champion trials, he said, aim to learn if the devices function as well as blood thinners and could be offered as an immediate alternative to blood thinners for everyone. Blood thinners, he said, carry various costs: among them are bleeding, clearances for dental work, pausing for surgical procedures, and the financial costs of being on the medications for life. If the trials prove the devices are as good as a blood thinner, a patient will have a choice. 'That's where these two trials are really pivotal in how we treat atrial fibrillation,' he said. The Champion trial – conducted at 141 locations, including Mon Medical – is complete and waiting on five-year results. Catalyst – being conducted at 132 locations, including Mon Medical – under way. Gharib said they have performed a number of procedures already and are still enrolling participants. He expects this portion of the trial will conclude at the end of the year. Volunteers are split into two groups: half get the Amulet, half get blood thinners. Participants have regular follow-up appointments for the five-year study period. Patients will know within a few weeks if the Amulet is working, he said, but the five-year period monitors long-term results and effects.
National Post
15-07-2025
- Health
- National Post
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
Article content Article content for the over one million cardiac surgery patients globally without a preoperative Afib diagnosis Article content MASON, Ohio — AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated in January 2023, LeAAPS enrolled 6,500 patients across 137 centers globally. Article content LeAAPS is a prospective, randomized, blinded, superiority, investigational device exemption (IDE) trial evaluating the AtriClip ® LAA Exclusion System for the prevention of ischemic stroke and systemic arterial embolism in cardiac surgery patients without a history of Afib—a large and often underserved population at elevated risk for these events. It is estimated that well over one million cardiac surgery procedures occur annually and more than 70% of these patients have no history of Afib before surgery. Article content 'The LeAAPS trial is a bold clinical evidence initiative that demonstrates AtriCure's unwavering commitment to improving care for cardiac surgery patients,' said Michael Carrel, President and CEO of AtriCure. 'The rapid pace of trial enrollment is a testament to the exceptional team of clinical trial investigators and broader clinician interest in changing the standard of care in cardiac surgery. LeAAPS presents an incredible opportunity to drive improved long-term outcomes for patients while significantly expanding our market leadership through the increased use of our AtriClip devices.' Article content Results of AtriCure's LeAAPS trial are expected to inform clinical practice and treatment guidelines for stroke prevention, using AtriClip platform technology, in patients undergoing planned cardiac surgery. The trial will continue with five years of follow-up to assess long-term outcomes. LeAAPS is being conducted in collaboration with the Population Health Research Institute (PHRI), affiliated with McMaster University in Hamilton, Ontario. PHRI brings extensive experience in designing and executing large-scale international clinical trials. Article content 'For decades, the medical community has sought to better understand the role of the LAA in stroke following cardiac surgery,' said Dr. Richard Whitlock, Cardiothoracic Surgeon at McMaster University and Global Principal Investigator for the trial. 'LeAAPS aims to deliver definitive evidence to guide optimal care for high-risk patients without Afib who may benefit from LAA exclusion.' Article content AtriCure first entered the LAA management market with FDA 510(k) clearance of the AtriClip System in 2010. Today, AtriClip devices are the most widely used LAA management device worldwide. The company plans to use LeAAPS data to support an expanded indication for stroke prevention in patients at elevated risk of ischemic stroke. Article content About AtriCure Article content AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure's Isolator ® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent and long-standing persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE ® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X @AtriCure. Article content Forward-Looking Statements Article content Certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data, including data that does not demonstrate sufficient safety and efficacy with respect to our products; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; the impact of tariffs or other restrictive trade measures; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ('SEC'), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 14, 2025, and our quarterly reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Article content Article content Article content Article content Article content Contacts Article content
Yahoo
23-05-2025
- Business
- Yahoo
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
MASON, Ohio, May 23, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X (formerly Twitter) @AtriCure. View source version on Contacts Angie WirickAtriCure, Financial Officer(513) 755-5334awirick@ Marissa BychGilmartin GroupInvestor Relationsmarissa@
